Rudd K.E. Johnson S.C. Agesa K.M. Shackelford K.A. Tsoi D. Kievlan D.R. Colombara D.V. Ikuta K.S. Kissoon N. Finfer S. Fleischmann-Struzek C. Machado F.R. Reinhart K.K. Rowan K. Seymour C.W. Watson R.S. West T.E. Marinho F. Hay S.I. Lozano R. Lopez A.D. Angus D.C. Murray C.J.L. Naghavi M.

Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the gobal burden of disease study.

Lancet (London, England). 395: 200-211Mayr F.B. Yende S. Angus D.C.

Epidemiology of severe sepsis.

Virulence. 5: 4-11Opal S.M. van der Poll T.

Endothelial barrier dysfunction in septic shock.

J Int Med. 277: 277-293Colbert J.F. Schmidt E.P.

Endothelial and microcirculatory function and dysfunction in sepsis.

Clinics Chest Med. 37: 263-275

Inflammation and coagulation.

Crit Care Med. 38: S26-34Katz J.N. Kolappa K.P. Becker R.C.

Beyond thrombosis: the versatile platelet in critical illness.

Chest. 139: 658-668

The immune system's role in sepsis progression, resolution, and long-term outcome.

Immunol Rev. 274: 330-353Shen X.F. Cao K. Jiang J.P. Guan W.X. Du J.F.

Neutrophil dysregulation during sepsis: an overview and update.

J Cell Mol Med. 21: 1687-1697Drifte G. Dunn-Siegrist I. Tissières P. Pugin J.

Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome.

Crit Care Med. 41: 820-832

Neutrophil migration under normal and sepsis conditions.

Cardiovasc Hematol Disord Drug Targets. 15: 19-28Hotchkiss R.S. Monneret G. Payen D.

Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.

Nat Rev Immunol. 13: 862-874Cicchese J.M. Evans S. Hult C. Joslyn L.R. Wessler T. Millar J.A. Marino S. Cilfone N.A. Mattila J.T. Linderman J.J. Kirschner D.E.

Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology.

Immunol Rev. 285: 147-167Rastogi D. Ratner A.J. Prince A.

Host-bacterial interactions in the initiation of inflammation.

Paediatr Respir Rev. 2: 245-252Dennis E.A. Cao J. Hsu Y.-H. Magrioti V. Kokotos G.

Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Chem Rev. 111: 6130-6185Balsinde Jesús Balboa María A. Insel a. Paul A. Dennis E.A.

Regulation and inhibition of phospholipase A2.

Annu Rev Pharmacol Toxicol. 39: 175-189

Biochemistry and physiology of mammalian secreted phospholipases A2.

Annu Rev Biochem. 77: 495-520

Lipidomic profiling of bioactive lipids by mass spectrometry during microbial infections.

Semin Immunol. 25: 240-248

Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.

J Clin Invest. 128: 2657-2669Dalli J. Colas R.A. Quintana C. Barragan-Bradford D. Hurwitz S. Levy B.D. Choi A.M. Serhan C.N. Baron R.M.

Human sepsis eicosanoid and proresolving lipid mediator temporal profiles: correlations with survival and clinical outcomes.

Crit Care Med. 45: 58-68Bruegel M. Ludwig U. Kleinhempel A. Petros S. Kortz L. Ceglarek U. Holdt L.M. Thiery J. Fiedler G.M.

Sepsis-associated changes of the arachidonic acid metabolism and their diagnostic potential in septic patients.

Crit Care Med. 40: 1478-1486Wang J. Sun Y. Teng S. Li K.

Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validation.

BMC Med. 18: 83Vardon Bounes F. Mémier V. Marcaud M. Jacquemin A. Hamzeh-Cognasse H. Garcia C. Series J. Sié P. Minville V. Gratacap M.-P. Payrastre B.

Platelet activation and prothrombotic properties in a mouse model of peritoneal sepsis.

Sci Rep. 8: 13536Claushuis T.A.M. van Vught L.A. Scicluna B.P. Wiewel M.A. Klein Klouwenberg P.M.C. Hoogendijk A.J. Ong D.S.Y. Cremer O.L. Horn J. Franitza M. Toliat M.R. Nürnberg P. Zwinderman A.H. Bonten M.J. Schultz M.J. van der Poll T. D. on behalf of the Molecular, and C. Risk Stratification of Sepsis

Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients.

Blood. 127: 3062-3072Larkin C.M. Santos-Martinez M.-J. Ryan T. Radomski M.W.

Sepsis-associated thrombocytopenia.

Thromb Res. 141: 11-16Ahmad N.S. Tan T.L. Arifin K.T. Ngah W.Z.W. Yusof Y.A.M.

High sPLA2-IIA level is associated with eicosanoid metabolism in patients with bacterial sepsis syndrome.

PLOS ONE. 15e0230285Willenberg I. Rund K. Rong S. Shushakova N. Gueler F. Schebb N.H.

Characterization of changes in plasma and tissue oxylipin levels in LPS and CLP induced murine sepsis.

Inflamm Res. 65: 133-142Awata W.M.C. Gonzaga N.A. Borges V.F. Silva C.B.P. Tanus-Santos J.E. Cunha F.Q. Tirapelli C.R.

Perivascular adipose tissue contributes to lethal sepsis-induced vasoplegia in rats.

Eur J Pharmacol. 863: 172706Höcherl K. Schmidt C. Kurt B. Bucher M.

Activation of the PGI2/IP system contributes to the development of circulatory failure in a rat model of endotoxic shock.

Hypertension. 52: 330-335

Arachidonic acid cytochrome P450 epoxygenase pathway.

J Lipid Res. 50: S52-56Wang P. Wang W. Hu Y. Li Y.

Prolonged Soluble Epoxide Hydrolase Reactivity in Brain Endothelial Cells Is Associated with Long Cognitive Deficits in Sepsis.

Mol Neurobiol. 57: 2846-2855Schmelzer K.R. Kubala L. Newman J.W. Kim I.H. Eiserich J.P. Hammock B.D.

Soluble epoxide hydrolase is a therapeutic target for acute inflammation.

Proc Natl Acad Sci U S A. 102: 9772-9777Chen Z. Tang Y. Yu J. Dong R. Yang Y. Fu M. Luo J. Hu S. Wang D.W. Tu L. Xu X.

sEH Inhibitor Tppu Ameliorates Cecal Ligation and Puncture-Induced Sepsis by Regulating Macrophage Functions.

Shock. 53: 761-771Brandt S.L. Serezani C.H.

Too much of a good thing: How modulating LTB(4) actions restore host defense in homeostasis or disease.

Semin Immunol. 33: 37-43Lee E.K.S. Gillrie M.R. Li L. Arnason J.W. Kim J.H. Babes L. Lou Y. Sanati-Nezhad A. Kyei S.K. Kelly M.M. Mody C.H. Ho M. Yipp B.G.

Leukotriene B4-mediated neutrophil recruitment causes pulmonary capillaritis during lethal fungal sepsis.

Cell Host Microbe. 23: 121-133.e4Monteiro A.P.T. Soledade E. Pinheiro C.S. Dellatorre-Teixeira L. Oliveira G.P. Oliveira M.G. Peters-Golden M. Rocco P.R.M. Benjamim C.F. Canetti C.

Pivotal role of the 5-lipoxygenase pathway in lung injury after experimental sepsis.

Am J Respir Cell Mol Biol. 50: 87-95Dalli J. Chiang N. Serhan C.N.

Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections.

Nat Med. 21: 1071-1075Riché F. Chousterman B.G. Valleur P. Mebazaa A. Launay J.-M. Gayat E.

Protracted immune disorders at one year after ICU discharge in patients with septic shock.

Critical care (London, England). 22: 42Spite M. Norling L.V. Summers L. Yang R. Cooper D. Petasis N.A. Flower R.J. Perretti M. Serhan C.N.

Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis.

Nature. 461: 1287-1291Chiang N. de la Rosa X. Libreros S. Serhan C.N.

Novel resolvin D2 receptor axis in infectious inflammation.

J Immunol. 198: 842-851

Phospholipid remodeling in physiology and disease.

Ann Rev Physiol. 81: 165-188Cho W.H. Park T. Park Y.Y. Huh J.W. Lim C.M. Koh Y. Song D.K. Hong S.B.

Clinical significance of enzymatic lysophosphatidylcholine (LPC) assay data in patients with sepsis.

Eur J Clin Microbiol Infect Dis. 31: 1805-1810Drobnik W. Liebisch G. Audebert F.-X. Fröhlich D. Glück T. Vogel P. Rothe G. Schmitz G.

Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients.

J Lipid Res. 44: 754-761Park J.-M. Noh J.-Y. Kim M.-J. Yun T.G. Lee S.-G. Chung K.S. Lee E.H. Shin M.H. Ku N.S. Yoon S. Kang M.-J. Park M.S. Pyun J.-C.

MALDI-TOF mass spectrometry based on parylene-matrix chip for the analysis of lysophosphatidylcholine in sepsis patient sera.

Anal Chem. 91: 14719-14727Mecatti G.C. Fernandes Messias M.C. Sant’Anna Paiola R.M. Figueiredo Angolini C.F. da Silva Cunha I.B. Eberlin M.N. de Oliveira Carvalho P.

Lipidomic profiling of plasma and erythrocytes from septic patients reveals potential biomarker candidates.

Biomark Insights. 13 ()Park D.W. Kwak D.S. Park Y.Y. Chang Y. Huh J.W. Lim C.-M. Koh Y. Song D.-K. Hong S.-B.

Impact of serial measurements of lysophosphatidylcholine on 28-day mortality prediction in patients admitted to the intensive care unit with severe sepsis or septic shock.

J Crit Care. 29 ()Ferrario M. Cambiaghi A. Brunelli L. Giordano S. Caironi P. Guatteri L. Raimondi F. Gattinoni L. Latini R. Masson S. Ristagno G. Pastorelli R.

Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach.

Sci Rep. 6: 20391Neugebauer S. Giamarellos-Bourboulis E.J. Pelekanou A. Marioli A. Baziaka F. Tsangaris I. Bauer M. Kiehntopf M.

Metabolite profiles in sepsis: developing prognostic tools based on the type of infection.

Crit Care Med. 44: 1649-1662Ahn W.-G. Jung J.-S. Kwon H.Y. Song D.-K.

Alteration of lysophosphatidylcholine-related metabolic parameters in the plasma of mice with experimental sepsis.

Inflammation. 40: 537-545Hong C.-W. Kim T.-K. Ham H.-Y. Nam J.-S. Kim Y.H. Zheng H. Pang B. Min T.-K. Jung J.-S. Lee S.-N. Cho H.-J. Kim E.-J. Hong I.-H. Kang T.-C. Lee J. Oh S.B. Jung S.J. Kim S.J. Song D.-K.

Lysophosphatidylcholine increases neutrophil bactericidal activity by enhancement of azurophil granule-phagosome fusion via glycine·GlyRα2/TRPM2/p38 MAPK signaling.

J Immunol. 184: 4401-4413Rolin J. Vego H. Maghazachi A.A.

Oxidized lipids and lysophosphatidylcholine induce the chemotaxis, up-regulate the expression of CCR9 and CXCR4 and abrogate the release of IL-6 in human monocytes.

Toxins. 6: 2840-2856Yan J.-J. Jung J.-S. Lee J.-E. Lee J. Huh S.-O. Kim H.-S. Jung K.C. Cho J.-Y. Nam J.-S. Suh H.-W. Kim Y.-H. Song D.-K.

Therapeutic effects of lysophosphatidylcholine in experimental sepsis.

Nat Med. 10: 161-167Smani Y. Domínguez-Herrera J. Ibáñez-Martínez J. Pachón J.

Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii.

Antimicrob Agents Chemother. 59: 3920-3924Murch O. Collin M. Sepodes B. Foster S.J. Mota-Filipe H. Thiemermann C.

Lysophosphatidylcholine reduces the organ injury and dysfunction in rodent models of gram-negative and gram-positive shock.

Br J Pharmacol. 148: 769-777Parra Millán R. Jiménez Mejías M.E. Sánchez Encinales V. Ayerbe Algaba R. Gutiérrez Valencia A. Pachón Ibáñez M.E. Díaz C. Pérez Del Palacio J. López Cortés L.F. Pachón J. Smani Y.

Efficacy of lysophosphatidylcholine in combination with antimicrobial agents against Acinetobacter baumannii in experimental murine peritoneal sepsis and pneumonia models.

Antimicrob Agents Chemother. 60: 4464-4470

Metabolism and atherogenic disease association of lysophosphatidylcholine.

Atherosclerosis. 208: 10-18Han J.H. Cao C. Kim S.M. Piao F.L. Kim S.H.

Attenuation of lysophosphatidylcholine-induced suppression of ANP release from hypertrophied atria.

Hypertension. 43: 243-248Cedars A. Jenkins C.M. Mancuso D.J. Gross R.W.

Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction.

J Cardiovasc Pharmacol. 53: 277-289Endo S. Inada K. Nakae H. Takakuwa T. Yamada Y. Suzuki T. Taniguchi S. Yoshida M. Ogawa M. Teraoka H.

Plasma levels of type II phospholipase A2 and cytokines in patients with sepsis.

Res Comm Molec Path Pharmacol. 90: 413-421Vadas P. Scott K. Smith G. Rajkovic I. Stefanski E. Schouten B.D. Singh R. Pruzanski W.

Serum phospholipase A2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shock.

Life Sci. 50: 807-811Green J.A. Smith G.M. Buchta R. Lee R. Ho K.Y. Rajkovic I.A. Scott K.F.

Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis.

Inflammation. 15: 355-367Levy R. Dana R. Hazan I. Levy I. Weber G. Smoliakov R. Pesach I. Riesenberg K. Schlaeffer F.

Elevated cytosolic phospholipase A(2) expression and activity in human neutrophils during sepsis.

Blood. 95: 660-665Uozumi N. Kita Y. Shimizu T.

Modulation of lipid and protein mediators of inflammation by cytosolic phospholipase A2 alpha during experimental sepsis.

J Immunol. 181: 3558-3566Yamashita A. Tanaka K. Kamata R. Kumazawa T. Suzuki N. Koga H. Waku K. Sugiura T.

Subcellular localization and lysophospholipase/transacylation activities of human group IVC phospholipase A2 (cPLA2gamma).

Biochim Biophys Acta. 1791: 1011-1022Tan T.L. Ahmad N.S. Nasuruddin D.N. Ithnin A. Tajul Arifin K. Zaini I.Z. Wan Ngah W.Z.

CD64 and Group II Secretory Phospholipase A2 (sPLA2-IIA) as Biomarkers for Distinguishing Adult Sepsis and Bacterial Infections in the Emergency Department.

PLoS One. 11e0152065

The role of group IIA secretory phospholipase A2 (sPLA2-IIA) as a biomarker for the diagnosis of sepsis and bacterial infection in adults-A systematic review.

PLoS One. 12e0180554Schrama A.J. de Beaufort A.J. Poorthuis B.J. Berger H.M. Walther F.J.

Secretory phospholipase A2 in newborn infants with sepsis.

J Perinatology. 28: 291-296Weinrauch Y. Abad C. Liang N.S. Lowry S.F. Weiss J.

Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phospholipase A2.

J Clin Invest. 102: 633-638Nevalainen T.J. Graham G.G. Scott K.F.

Antibacterial actions of secreted phospholipases A2.

Biochim Biophys Acta. 1781: 1-9Movert E. Wu Y. Lambeau G. Kahn F. Touqui L. Areschoug T.

Secreted group IIA phospholipase A2 protects humans against the group B streptococcus: experimental and clinical evidence.

J Infect Dis. 208: 2025-2035Liu M.S. Liu C.H. Wu G. Zhou Y.

Antisense inhibition of secretory and cytosolic phospholipase A2 reduces the mortality in rats with sepsis.

Crit Care Med. 40: 2132-2140Zeiher B.G. Steingrub J. Laterre P.F. Dmitrienko A. Fukiishi Y. Abraham E. E. S. Group

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis.

Crit Care Med. 33: 1741-1748Lordan R. Tsoupras A. Zabetakis I. Demopoulos C.A.

Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.

Molecules. 24: 4414Prescott S.M. Zimmerman G.A. Stafforini D.M. McIntyre T.M.

Platelet-activating factor and r elated lipid mediators.

Annu Rev Biochem. 69: 419-445Wykle R.L. Malone B. Snyder F.

Enzymatic synthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid.

J Biol Chem. 255: 10256-10260Holland M.R. Venable M.E. Whatley R.E. Zimmerman G.A. McIntyre T.M. Prescott S.M.

Activation of the acetyl-coenzyme A:lysoplatelet-activating factor acetyltransferase regulates platelet-activating factor synthesis in human endothelial cells.

J Biol Chem. 267: 22883-22890Lee T.C. Malone B. Snyder F.

A new de novo pathway for the formation of 1-alkyl-2-acetyl-sn-glycerols, precursors of platelet activating factor. Biochemical characterization of 1-alkyl-2-lyso-sn-glycero-3-P:acetyl-CoA acetyltransferase in rat spleen.

J Biol Chem. 261: 5373-5377Triggiani M. Schleimer R.P. Warner J.A. Chilton F.H.

Differential synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine and platelet-activating factor by human inflammatory cells.

J Immunol. 147: 660-666Watanabe J. Marathe G.K. Neilsen P.O. Weyrich A.S. Harrison K.A. Murphy R.C. Zimmerman G.A. McIntyre T.M.

Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles.

J Biol Chem. 278: 33161-33168Prescott S.M. Zimmerman G.A. McIntyre T.M.

Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin.

Proc Natl Acad Sci U S A. 81: 3534-3538Muller E. Dagenais P. Alami N. Rola-Pleszczynski M.

Identification and functional characterization of platelet-activating factor receptors in human leukocyte populations using polyclonal anti-peptide antibody.

Proc Natl Acad Sci U S A. 90: 5818-5822Honda Z. Nakamura M. Miki I. Minami M. Watanabe T. Seyama Y. Okado H. Toh H. Ito K. Miyamoto T. et al.

Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung.

Nature. 349: 342-346Zimmerman G.A. McIntyre T.M. Prescott S.M.

Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro.

J Clin Invest. 76: 2235-2246Lorant D.E. Patel K.D. McIntyre T.M. McEver R.P. Prescott S.M. Zimmerman G.A.

Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils.

J Cell Biol. 115: 223-234Weyrich A.S. McIntyre T.M. McEver R.P. Prescott S.M. Zimmerman G.A.

Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation.

J Clin Invest. 95: 2297-2303Rouis M. Nigon F. Chapman M.J.

Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophages.

Biochem Biophys Res Commun. 156: 1293-1301Takahashi S. Yoshikawa T. Naito Y. Tanigawa T. Yoshida N. Kondo M.

Role of platelet-activating factor (PAF) in superoxide production by human polymorphonuclear leukocytes.

Lipids. 26: 1227-1230Yost C.C. Cody M.J. Harris E.S. Thornton N.L. McInturff A.M. Martinez M.L. Chandler N.B. Rodesch C.K. Albertine K.H. Petti C.A. Weyrich A.S. Zimmerman G.A.

Impaired neutrophil extracellular trap (NET) formation: a novel innate immune deficiency of human neonates.

Blood. 113: 6419-6427Zhou W. Javors M.A. Olson M.S.

Platelet-activating factor as an intercellular signal in neutrophil-dependent platelet activation.

J Immunol. 149: 1763-1769Ninio E. Leyravaud S. Bidault J. Jurgens P. Benveniste J.

Cell adhesion by membrane-bound paf-acether.

Int Immunol. 3: 1157-1163Yost C.C. Weyrich A.S. Zimmerman G.A.

The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses.

Biochimie. 92: 692-697Ishii S. Nagase T. Tashiro F. Ikuta K. Sato S. Waga I. Kume K. Miyazaki J. Shimizu T.

Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor.

EMBO J. 16: 133-142Jeong Y.I. Jung I.D. Lee C.M. Chang J.H. Chun S.H. Noh K.T. Jeong S.K. Shin Y.K. Lee W.S. Kang M.S. Lee S.Y. Lee J.D. Park Y.M.

The novel role of platelet-activating factor in protecting mice against lipopolysaccharide-induced endotoxic shock.

PLoS One. 4e6503Stafforini D.M. McIntyre T.M. Zimmerman G.A. Prescott S.M.

Platelet-activating factor acetylhydrolases.

J Biol Chem. 272: 17895-17898Stafforini D.M. McIntyre T.M. Carter M.E. Prescott S.M.

Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.

J Biol Chem. 262: 4215-4222Blank M.L. Lee T. Fitzgerald V. Snyder F.

A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid).

J Biol Chem. 256: 175-178Farr R.S. Wardlow M.L. Cox C.P. Meng K.E. Greene D.E.

Human serum acid-labile factor is an acylhydrolase that inactivates platelet-activating factor.

Fed Proc. 42: 3120-3122Teixeira-da-Cunha M.G. Gomes R.N. Roehrs N. Bozza F.A. Prescott S.M. Stafforini D. Zimmerman G.A. Bozza P.T. Castro-Faria-Neto H.C.

Bacterial clearance is improved in septic mice by platelet-activating factor-acetylhydrolase (PAF-AH) administration.

PLoS One. 8e74567Gomes R.N. Bozza F.A. Amancio R.T. Japiassu A.M. Vianna R.C. Larangeira A.P. Gouvea J.M. Bastos M.S. Zimmerman G.A. Stafforini D.M. Prescott S.M. Bozza P.T. Castro-Faria-Neto H.C.

Exogenous platelet-activating factor acetylhydrolase reduces mortalit